Personally, if Matt isn't forthcoming re. specifically how the company plans to address the looming cash shortfall then I will liquidate all but my 2018 .50 calls. Either there is genuine 'aggressive' interest by foreign pharmaceutical entities - and by aggressive I mean interest which involves a willingness to pony up considerable upfront cash, or a willingness to take on a serious equity stake, or there isn't. I am sick to death of excuses from Matt, of the ridiculous cloak-n-dagger manner in which MNKD has been run for years. There are too many other sig. undervalued biotech's with near-term catalysts - one's with dynamic, smart, shareholder friendly CEO's who have a proven track record of delivering vs one of repeated failure to deliver. IMO, 4 months is enough time to get at least one international partner - if Matt was paying sufficient attention over the last year he would already have had a 'plan' B ready for launch in the eventuality of Sanofi's withdrawal - it was obvious to most all of us here what was likely coming from Sanofi.
Only change for today is a couple hundred shares available - same 107% cost to borrow.
You don't think a simple verbal update would suffice - has to be a visual presentation? A simple announcement of the first international deal with $150M upfront would do it for me.
Nobody is asking why MNKD is tanking dufffus newborn - we know why, and we don't care if it drops, even back to 65 cents. International catalysts are likely only a couple months out, maybe even a couple weeks out.
Please please work harder to smash the price back below $1 BEFORE the first deal is announced.
A re-test of around 65 cents would be such an incredible gift.
Word of Afrezza's amazingly superior real world efficacy and safety is getting out, albeit much more slowly than we had once hoped. One by one, Endos will see, and hardly be able to believe at first, Afrezza's true superiority - and they will be won over.
If there is dilution, and even a R/S before traction is regained - so be it.
Sentiment: Strong Buy
Charge has been slowly moving up of late from ~ 95% recently.
High charge was up to 142% for a couple of days a few months back.
Honestly 80%-plus is not really all that much to pay for shares in such short supply.
Seems obvious - company is being sold and he is looking for a new position where he can put his M&A skills to further use........not rocket science mate.